CINECA IRIS Institutional Research Information System

BONORA, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 28.749
EU - Europa 16.284
AS - Asia 13.913
SA - Sud America 2.113
Continente sconosciuto - Info sul continente non disponibili 1.907
AF - Africa 524
OC - Oceania 100
Totale 63.590
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 27.804
SG - Singapore 5.136
CN - Cina 4.345
IT - Italia 4.307
DK - Danimarca 1.833
DE - Germania 1.599
BR - Brasile 1.532
FR - Francia 1.500
IE - Irlanda 1.325
VN - Vietnam 1.323
SE - Svezia 1.094
FI - Finlandia 996
GB - Regno Unito 780
UA - Ucraina 747
KR - Corea 703
IN - India 478
CA - Canada 466
AT - Austria 455
PL - Polonia 368
HK - Hong Kong 360
NL - Olanda 280
JP - Giappone 270
ES - Italia 253
ID - Indonesia 248
BD - Bangladesh 230
MX - Messico 194
ZA - Sudafrica 188
AR - Argentina 177
RU - Federazione Russa 154
IQ - Iraq 106
BE - Belgio 97
RO - Romania 94
CO - Colombia 93
AU - Australia 89
TW - Taiwan 88
PK - Pakistan 87
JM - Giamaica 85
TR - Turchia 84
TH - Thailandia 83
CL - Cile 79
CH - Svizzera 78
EC - Ecuador 65
PE - Perù 63
CZ - Repubblica Ceca 54
PH - Filippine 47
VE - Venezuela 47
GR - Grecia 46
MA - Marocco 45
UZ - Uzbekistan 42
CR - Costa Rica 40
PT - Portogallo 39
IR - Iran 34
SA - Arabia Saudita 34
IL - Israele 32
KE - Kenya 32
EG - Egitto 25
NG - Nigeria 24
MY - Malesia 23
SN - Senegal 23
EU - Europa 22
JO - Giordania 22
TT - Trinidad e Tobago 22
UG - Uganda 22
AE - Emirati Arabi Uniti 21
DZ - Algeria 21
ET - Etiopia 21
LT - Lituania 21
BO - Bolivia 19
HN - Honduras 19
HR - Croazia 19
HU - Ungheria 19
PY - Paraguay 19
SD - Sudan 19
TN - Tunisia 19
PR - Porto Rico 18
BG - Bulgaria 17
GT - Guatemala 17
NO - Norvegia 17
UY - Uruguay 17
NP - Nepal 16
DO - Repubblica Dominicana 14
SK - Slovacchia (Repubblica Slovacca) 13
AZ - Azerbaigian 12
KZ - Kazakistan 12
LV - Lettonia 12
PA - Panama 12
NZ - Nuova Zelanda 11
RS - Serbia 11
SV - El Salvador 11
AL - Albania 10
BY - Bielorussia 10
NI - Nicaragua 10
SY - Repubblica araba siriana 10
GE - Georgia 8
MD - Moldavia 8
MU - Mauritius 8
OM - Oman 8
TZ - Tanzania 8
BB - Barbados 7
LA - Repubblica Popolare Democratica del Laos 7
Totale 61.532
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.773
Singapore 2.791
Beijing 2.636
Chandler 1.953
Ashburn 1.870
San Jose 1.569
Dublin 1.317
Houston 1.218
Santa Clara 1.159
Fairfield 883
Milan 648
Villeurbanne 622
Wilmington 601
Torino 554
Jacksonville 541
Dearborn 480
Medford 471
Princeton 443
Woodbridge 435
Council Bluffs 424
Redwood City 384
Columbus 383
Ho Chi Minh City 381
Seattle 379
The Dalles 360
Los Angeles 345
Vienna 343
Lauterbourg 332
Warsaw 329
Nyköping 314
Turin 313
Rome 312
New York 304
Hong Kong 286
Cambridge 273
Helsinki 268
Hanoi 260
Buffalo 258
Dallas 241
Seoul 197
Hefei 192
Pisa 187
Munich 180
São Paulo 170
Boardman 165
Boston 162
Jakarta 143
Tokyo 142
Fremont 130
Guangzhou 126
Toronto 120
Dong Ket 116
Frankfurt am Main 115
Chicago 113
Nuremberg 113
Bengaluru 110
Shanghai 103
Verona 101
London 80
Paris 78
Orem 75
Washington 74
San Diego 73
Montreal 70
Naples 70
Nanjing 69
Hangzhou 67
Rio de Janeiro 67
Bologna 66
Brussels 65
Phoenix 65
Atlanta 64
Cape Town 64
Philadelphia 57
Da Nang 56
San Francisco 56
Kingston 54
Redondo Beach 53
Taipei 53
Norwalk 52
Turku 52
Florence 51
Kunming 51
Memphis 50
Amsterdam 49
Santiago 49
Lima 48
Mexico City 47
Palermo 46
Brooklyn 45
Haiphong 44
Manchester 41
Mumbai 41
Omaha 40
Buenos Aires 39
Madrid 39
Chennai 38
Nürnberg 38
Ottawa 38
Silver Spring 38
Totale 35.450
Salva come PNG Salva come JPEG
Nome #
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? 953
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. 847
Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS 699
Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era 634
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 557
High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: A meta-analysis 530
Cerebrospinal Fluid Inhibitory Quotients of Antiretroviral Drugs in HIV-positive Patients are Associated with Compartmental Viral Control. 520
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment 518
Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients 440
A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs 431
HIV-1 Very Low Level Viremia is Associated with Virological Failure in HAART-treated Patients 424
Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. 422
Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV 417
Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study 409
Heart failure in patients with human immunodeficiency virus: a review of the literature. 400
High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. 390
Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. 374
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose 364
Tenofovir clearance is reduced in hiv-positive patients with subclinical tubular impairment 356
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting 349
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 337
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis 328
A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease 319
Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. 313
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) 313
Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and Inflammation 309
Are intracellular drug concentrations underestimated? The role of medium corpuscular volume (MCV) for a correct determination 308
Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients 306
Raltegravir penetration in seminal plasma of healthy volunteers. 300
Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid 299
Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. 291
In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis 290
Prevalence and predictors of blood-brain barrier damage in the HAART era. 288
Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV 284
Acute HIV infection: Improved algorithms for HIV testing. 279
Single-nucleotide polymorphisms ABCB1 3435C>T, 1236C>T and CYP2B6 516G>T influence plasma concentrations of Efavirenz (EFV). 277
Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia 273
Pharmacogenetics of Antiretrovirals' Penetrations into Cerebrospinal Fluid 268
Extra Corporeal Membrane Oxygenation (ECMO) in three HIV-positive patients with acute respiratory distress syndrome 263
Descrittiva della farmacocinetica (PK) e della farmacogenetica (PG) dell'Efavirenz in una coorte di popolazione italiana 255
Effect of Darunavir (DRV) genotypic inhibitory quotient (gIQ) on the virological response to DRV-containing salvage regimens at 24 weeks 254
SLC28A2 65C>T predict Sustained Virological Response in patients with hepatitis C treated with interferon and ribavirin, considering all HCV genotype and genotype 1/4. 252
A pilot study evaluating plasma and intracellular pharmacokinetics (PK) of switching from atazanavir (ATV) 400mg QD to ATV 200 mg BID in HIV+ patients. 250
TENOFOVIR AND EMTRICITABINE CSF-TO-PLASMA RATIOS CORRELATE TO THE EXTENT OF BLOOD BRAIN-BARRIER DAMAGE 247
A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. 245
Etravirine Plasma Exposure is Associated with Virological Efficacy in Treatment-experienced HIV-positive Patients. 244
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance 243
Cardiovascular disease in HIV patients: from bench to bedside and backwards 240
A filter-based cross-sectional analysis of an HIV-positive, HAART-treated cohort in rural Burundi: pharmacokinetics, pharmacogenetics and viral load 239
An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients 238
Could ritonavir intracellular concentrations have a role as active drugs when used as a booster PIs? 237
Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. 236
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines 236
West African Immigrants and New Patterns of Malaria Imported to North Eastern Italy. 234
Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting 229
Pharmacokinetics of the Dual NRTI- and Protease Inhibitor-sparing Regimen Raltegravir plus Nevirapine in HIV-1+ Patients 229
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014 229
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting 229
Determinants of Tenofovir Plasma Trough Concentrations: a Cross-sectional Analysis in the Clinical Setting 229
A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. 229
Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens 227
Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. 224
INTRACELLULAR ACCUMULATION OF RITONAVIR ASSOCIATED WITH DIFFERENT BOOSTED PIS 224
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 223
SLC29A1 −706G>C predict haemoglobin decrease in patients with hepatitis C treated with interferon and ribavirin 220
Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy? 220
Role of therapeutic drug monitoring in a patient with human immunodeficiency virus infection and end-stage liver disease undergoing orthotopic liver transplantation 218
Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients 217
Pharmacokinetics of Raltegravir, Etravirine and Maraviroc regimen in the clinical setting 216
Pharmacokinetic Determinants of Immunovirological Response in HIV Very Late Presenters 215
Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. 215
Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study. 214
Failure of prophylaxis against PCP in patients with HIV infection. 213
Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-sectional Study in HIV-positive Patients with Normal Renal Function. 211
Pharmacokinetics (PK) of the co-administration of raltegravir (RAL) and amlodipine (AML) to male and female healthy volunteers 211
GREATER IMMUNOLOGICAL RECOVERY ASSOCIATED WITH ADDITIONAL ENFUVIRTIDE IN THE TREATMENT OF NAIVE HIV-INFECTED PATIENTS AT VERY ADVANCED DISEASE STAGES: 24-WEEK RESULTS OF A RANDOMIZED, CONTROLLED, PILOT STUDY 211
Undetectable Ritonavir Plasma Concentrations in Different Boosted PI-based Regimens as a Marker of Non-Adherence: analysis of a large TDM Registry 210
Single-nucleotide polymorphism PXR 7635G>A influences plasma concentrations of Efavirenz in CYP2B6 516G>T carriers 209
MONITORING OF VIROLOGICAL AND PHARMACOLOGICAL CEREBROSPINAL FLUID PARAMETERS IN HAART-TREATED HIV-POSITIVE PATIENTS IN THE CLINICAL SETTING 207
Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. 205
High incidence of infections in HIV-positive patients treated for lymphoproliferative disorders 205
Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. 205
Steady-state Raltegravir Penetration in Seminal Plasma of Healthy Volunteers 204
Medication Burden and Clustering in People Living with HIV Undergoing Therapeutic Drug Monitoring 204
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. 203
Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics 203
HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients 203
An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients 202
AISF position paper on HCV in immunocompromised patients 202
Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. 200
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. 199
What do we know about tailoring treatment with tenofovir? 198
Efficacy, Safety and Pharmacokinetics of Atazanavir (200 mg twice-daily) plus Raltegravir (400 mg twice-daily) Dual Regimen in the Clinical Setting 197
Directly active antivirals pharmacokinetics in HCV/HIV co-infected patients with advanced hepatic fibrosis 197
Clinical pharmacology of complex regiment of antiretroviral therapy including Etravirine, Maraviroc and Raltégravir. 197
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. 194
A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era. 193
Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject 193
Intracellular accumulation of the new integrase inhibitors elvitegravir and dolutegravir in HIV patients 191
Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients 190
Totale 28.993
Salva come PNG Salva come JPEG
Categoria #
all - tutte 184.208
article - articoli 0
book - libri 0
conference - conferenze 34.542
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 218.750
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.302 0 0 545 604 429 439 562 512 352 256 714 889
2022/20236.212 631 368 123 579 651 1.584 462 455 676 122 330 231
2023/20242.828 355 457 158 159 240 402 78 180 55 119 233 392
2024/20257.211 117 318 306 648 1.621 458 220 467 816 467 589 1.184
2025/202616.181 1.327 725 900 1.737 1.635 738 2.143 665 1.234 1.328 898 2.851
2026/20272.638 688 1.359 591 0 0 0 0 0 0 0 0 0
Totale 63.590